Aura Biosciences (AURA) Income towards Parent Company (2020 - 2026)
Aura Biosciences (AURA) posted Income towards Parent Company of -$33.7 million for Q1 2026, down 142.28% on a QoQ basis from $79.7 million in Q4 2025, and down 22.57% year-over-year from -$43.5 million in Q1 2025.
Aura Biosciences (AURA) Income towards Parent Company (2020 - 2026) Analysis & Trends
Aura Biosciences' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$33.7 million for Q1 2026.
- Quarterly Income towards Parent Company fell 22.57% year-over-year to -$33.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.2 million (up 92.52% YoY) and the FY2025 annual result came in at -$958000.0, up 98.91% from the prior year.
- Income towards Parent Company was -$33.7 million for Q1 2026 at Aura Biosciences, down from $79.7 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $79.7 million in Q4 2025 and bottomed at -$74.3 million in Q1 2022.
- A 5-year average of -$23.0 million and a median of -$22.1 million in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company slumped 1135.3% — and 2025, when it jumped 396.12%.
- Aura Biosciences' Income towards Parent Company stood at -$18.4 million in 2022, then declined by 20.4% to -$22.1 million in 2023, then fell by 21.58% to -$26.9 million in 2024, then jumped by 396.12% to $79.7 million in 2025, then plunged by 142.28% to -$33.7 million in 2026.
- Business Quant data shows AURA's Income towards Parent Company at -$33.7 million in Q1 2026, $79.7 million in Q4 2025, and -$26.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Aura Biosciences | 484.61 Mn | 399.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.69 Mn |
| Dec 31, 2025 | 79.67 Mn |
| Sep 30, 2025 | -26.13 Mn |
| Jun 30, 2025 | -27.02 Mn |
| Mar 31, 2025 | -27.48 Mn |
| Dec 31, 2024 | -26.91 Mn |
| Sep 30, 2024 | -21.04 Mn |
| Jun 30, 2024 | -20.34 Mn |
| Mar 31, 2024 | -19.71 Mn |
| Dec 31, 2023 | -22.13 Mn |
| Sep 30, 2023 | -18.51 Mn |
| Jun 30, 2023 | -18.30 Mn |
| Mar 31, 2023 | -17.47 Mn |
| Dec 31, 2022 | -18.38 Mn |
| Sep 30, 2022 | -59.05 Mn |
| Jun 30, 2022 | -40.96 Mn |
| Mar 31, 2022 | -74.30 Mn |
| Dec 31, 2021 | -11.78 Mn |
| Sep 30, 2021 | -22.95 Mn |
| Jun 30, 2021 | -8.80 Mn |